Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.83 |
| ▸ | BLM | P54132 | 2/20 | 0.83 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxylamine SCHEMBL30702275 | 1.00 | CHRM2 (1.00) | CHRM2CYP2D6BLMCHRM4CHRM5 | |
| Doxylamine SCHEMBL4709 | 1.00 | CHRM2 (1.00) | CHRM2CYP2D6BLMCHRM4CHRM5 | |
| Doxylamine SCHEMBL30116312 | 1.00 | CHRM2 (1.00) | CHRM2CYP2D6BLMCHRM4CHRM5 | |
| Doxylamine SCHEMBL17047020 | 0.99 | CHRM2 (0.97) | CHRM2CYP2D6BLMCHRM4CHRM5 | |
| Doxylamine SCHEMBL1172924 | 0.91 | BLM (1.00) | CHRM2CYP2D6BLMCHRM4CHRM5 | |
| Doxylamine SCHEMBL17540680 | 0.91 | BLM (1.00) | CHRM2CYP2D6BLMCHRM4CHRM5 | |
| Doxylamine SCHEMBL160443 | 0.91 | BLM (1.00) | CHRM2CYP2D6BLMCHRM4CHRM5 | |
| Doxylamine SCHEMBL17558540 | 0.89 | CHRM2 (0.79) | CHRM2CYP2D6BLMCHRM4CHRM5 | |
| Doxylamine SCHEMBL21435766 | 0.86 | CHRM2 (0.74) | CHRM2CYP2D6BLMCHRM4CHRM5 | |
| Moxastine SCHEMBL29281 | 0.84 | CHRM2 (0.71) | CHRM2CYP2D6BLMCHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458201-B2 | Mucosal active agent delivery | SUDA LTD. (AU) | 2022-10-04 | — | — | US | disclosed |
| US-9456985-B2 | Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug | UPSHER-SMITH LABORATORIES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9456985-B2 | Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug | UPSHER-SMITH LABORATORIES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150238423-A1 | Sustained-Released Product Comprising a Combination of a Non-Opioid Amine and a Non-Steroidal, Anti-Inflammatory Drug | UPSHER-SMITH LABORATORIES, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150238423-A1 | Sustained-Released Product Comprising a Combination of a Non-Opioid Amine and a Non-Steroidal, Anti-Inflammatory Drug | UPSHER-SMITH LABORATORIES, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-9023390-B2 | Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug | UPSHER-SMITH LABORATORIES, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023390-B2 | Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug | UPSHER-SMITH LABORATORIES, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120252833-A1 | SUSTAINED-RELEASE PRODUCT COMPRISING A COMBINATION OF A NON-OPIOID AMINE AND A NON-STERIODAL ANTI-INFLAMMATORY DRUG | UPSHER-SMITH LABORATORIES, INC. (US) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252833-A1 | SUSTAINED-RELEASE PRODUCT COMPRISING A COMBINATION OF A NON-OPIOID AMINE AND A NON-STERIODAL ANTI-INFLAMMATORY DRUG | SIGMAR1, OPRM1, OPRK1 | HRH1 621/4885CHRM2 902/4885CYP2D6 70/4885 |
| US-20150238423-A1 | Sustained-Released Product Comprising a Combination of a Non-Opioid Amine and a Non-Steroidal, Anti-Inflammatory Drug | OPRK1, OPRM1, SIGMAR1 | HRH1 281/4885CHRM2 524/4885CYP2D6 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.